# A Study of Olaratumab (IMC-3G3) in Prostate Cancer

> **NCT01204710** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 123 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Olaratumab
- **DRUG:** Mitoxantrone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01204710
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-09
- **Final completion:** 2013-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204710, "A Study of Olaratumab (IMC-3G3) in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01204710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*